Horizon Kinetics Medical ETF (MEDX)
- Previous Close
27.49 - Open
27.40 - Bid 25.59 x 100
- Ask 29.46 x 100
- Day's Range
27.40 - 27.44 - 52 Week Range
27.02 - 32.16 - Volume
128 - Avg. Volume
796 - Net Assets 17.74M
- NAV 27.50
- PE Ratio (TTM) 17.19
- Yield 1.30%
- YTD Daily Total Return -1.77%
- Beta (5Y Monthly) 0.56
- Expense Ratio (net) 0.85%
The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.
Horizon Kinetics
Fund Family
Health
Fund Category
17.74M
Net Assets
1999-09-30
Inception Date
Performance Overview: MEDX
Trailing returns as of 4/18/2024. Category is Health.
People Also Watch
Holdings: MEDX
Top 10 Holdings (61.67% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: MEDX
NBIX: Lowering target price to $140.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $140.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingNeutralPrice TargetLGND: Lowering target price to $84.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetLGND: Raising target price to $86.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetMYGN: Lowering target price to $19.00
MYRIAD GENETICS INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingBearishPrice Target